Rapid Micro Biosystems (RPID)

The company’s main platform is the Growth Direct system, which automates key parts of microbial enumeration and detection. Traditional microbial testing often relies on manual inspection of culture plates by trained laboratory staff, a process that can be time-consuming and subject to variability. Rapid Micro Biosystems uses imaging technology and the natural autofluorescence of living cells to identify microbial growth earlier and with greater consistency than visual inspection alone.

In addition to its instruments, the company sells proprietary consumables, software, services, and laboratory information management system connectivity. These elements are intended to fit into regulated manufacturing environments, where documentation, data integrity, repeatability, and compliance with quality standards are central requirements. By automating routine testing, the Growth Direct platform can help laboratories reduce manual workloads, standardise processes, and obtain results more efficiently.

Rapid Micro Biosystems is based in the United States and generates most of its revenue domestically, while also serving customers in markets such as Switzerland, Germany, Japan, and other international regions. Its customer base is tied to industries where microbial contamination can affect product safety, batch release, and regulatory compliance.

The company trades under the ticker RPID. Its distinctive position lies at the intersection of microbiology, automation, and regulated manufacturing, offering technology that modernises a historically manual part of quality control testing.